Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?
Reactivation of hepatitis B infection is an increasing problem for patients with lymphoma, even in resolved infections, who were treated with rituximab-based regimens. Our cases point out the need of prolonged prophylaxis in HBsAg-negative patients due to the high risk of developing fatal reactivation.
Garcia-Rodriguez
Maria J
MJ
Servicio de Hematologia, Hospital Universitario La Paz, Madrid, Spain. mj.garciarodriguez@gmail.com
Canales
Miguel A
MA
Hernandez-Maraver
Dolores
D
Hernandez-Navarro
Fernando
F
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006509:Hepatitis B / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D000069283:Rituximab; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; C413685:entecavir; D006147:Guanine